Skip to content

Assessment of Sleep Quality in Patients Treated for Cancer Between 15 and 24 Years of Age

Assessment of Sleep Quality in Patients Treated for Cancer Between 15 and 24 Years of Age

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06904495
Acronym
SOM'AJA
Enrollment
400
Registered
2025-04-01
Start date
2025-04-15
Completion date
2026-05-05
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Survivors

Brief summary

Medical professionals now take into account the specificities of the care and support of Adolescents and Young Adults (AYAs). Cancer aftermaths in patients diagnosed during the AYA period are also known: the consequences of chemotherapy and radiotherapy treatments on a growing organism, the difficulty of some follow-ups, the longevity, and the delayed occurrence of certain complications. In the general population, sleep disorders affect 40% of adolescents. About 30% of pediatric cancer survivors experience fatigue they attribute to their cancer, even years after the end of their treatment. The sleep quality of patients treated for cancer when they were AYAs, and the eventual care of sleeping disorders, are poorly studied. The investigators suppose that the oncologic treatment during this particular life stage, when sleeping disorders are already present and multifactorial, could have long-term impacts on sleep. The investigators offer to evaluate, through a questionnaire filled out by patients treated for cancer in the AYA period, the frequency of moderate to severe insomnia.

Interventions

OTHERSurvey of sleep quality and associated factors

Sleep quality and associated factors (anxiety, depression, and pain) will be evaluated through an online survey on the Reseau Morphee platform, through an self-administered evaluation of the patients' pain and sleep difficulties, and a precarity scale.

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to 24 Years
Healthy volunteers
No

Inclusion criteria

* Patient treated for a cancer * Patient aged between 15 and 24 years old at the time of the diagnosis * Patients whom intensive treatment ended at least 3 months ago * Patient followed in a PACAAURA cancerology center * Life expectancy ≥ 6 months * Karnosky index \> 60% * Patient who agrees to participate in the program and benefits from social security * Patient able to understand, speak and read French. * No major cognitive impairment (assessed by the patient's referees) * No sensory disability

Exclusion criteria

* Patient unable to use informatic tools * Known superior cognitive function disorders * Progressive psychiatric pathology * Drug user or alcohol abuse

Design outcomes

Primary

MeasureTime frameDescription
Number of patients presenting moderate or severe insomniaDay 1Online self-administered questionnaire filled-out by the patient (120 questions) Scores between 1 and 10, yes or no, multiple choice questions, open-ended questions

Secondary

MeasureTime frameDescription
Identification of sleep disorders risk factorsDay 1Self-administered questionnaire filled-out by the patient (120 questions) self-administered evaluation of the patients' pain and sleep difficulties Precarity scale Scores between 1 and 10, yes or no, multiple choice questions, open-ended questions

Countries

France

Contacts

CONTACTMeryl Horwitz, Dr
horwitez.m@chu-nice.fr492036795

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026